CHASE Pharmaceuticals
Washington, US · 2 known investors
Founders & leadership
TN
Thomas N. ChaseFounder
DI
Douglas IngramExecutive
KC
Kathleen Clarence-SmithNamed on SEC filing
GN
Greg N. ParekhNamed on SEC filing
JM
John M. SiebertNamed on SEC filing
Board
NG
Nayan Greg ParekhBoard director
JM
RW
Raphael WisniewskiBoard director
SC
Stephen CunninghamBoard director
VS
Vikram SudarsanBoard director
KN
Karoly NikolichBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$21.6M disclosed across 3 of 5 rounds · 2014–2016
▶$12MraisedMar 2016 · 14 investors · PharmaceuticalsRule 506(b)
▶$12MraisedMar 2016 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kathleen Clarence-SmithExecutive Officer
- Vikram SudarsanDirector
- Raphael WisniewskiDirector
- Stephen CunninghamDirector
- Nayan Greg ParekhDirector
- Karoly NikolichDirector
- John M. ReherDirector
- Thomas N. ChaseExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $12M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$106.7KofferedFeb 2016 · 3 investors · PharmaceuticalsRule 506(b)
▶$106.7KofferedFeb 2016 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephen CunninghamDirector
- Raphael WisniewskiDirector
- Vikram SudarsanDirector
- Nayan Greg ParekhDirector
- John M. ReherDirector
- Thomas N. ChaseExecutive Officer, Director
- Karoly NikolichDirector
- Kathleen Clarence-SmithExecutive Officer
- Douglas IngramExecutive Officer, Director
- Offering amount
- $106.7K
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedFeb 2016 · 13 investors · PharmaceuticalsRule 506(b)
▶$3.5MraisedFeb 2016 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Raphael WisniewskiDirector
- Vikram SudarsanDirector
- Stephen CunninghamDirector
- Nayan Greg ParekhDirector
- John M. ReherDirector, Executive Officer
- Thomas N. ChaseExecutive Officer, Director
- Karoly NikolichDirector
- Douglas IngramDirector
- Kathleen Clarence-SmithExecutive Officer
- Offering amount
- $3.5M
- Amount sold
- $3.5M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$612.5KofferedFeb 2016 · 1 investors · PharmaceuticalsRule 506(b)
▶$612.5KofferedFeb 2016 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Nayan Greg ParekhDirector
- Karoly NikolichDirector
- Kathleen Clarence-SmithExecutive Officer
- John M. ReherDirector
- Raphael WisniewskiDirector
- Douglas IngramExecutive Officer, Director
- Thomas N. ChaseExecutive Officer, Director
- Stephen CunninghamDirector
- Vikram SudarsanDirector
- Offering amount
- $612.5K
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.1MraisedMay 2014 · 6 investors · PharmaceuticalsRule 506(b)
▶$6.1MraisedMay 2014 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Raphael WisniewskiDirector
- Greg N. ParekhDirector
- Vikram SudarsanDirector
- Thomas N. ChaseDirector
- John M. ReherDirector
- John M. SiebertExecutive Officer, Director
- Karoly NikolichDirector
- Offering amount
- $8.6M
- Amount sold
- $6.1M
- Minimum investment
- $1
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded CHASE Pharmaceuticals?
- CHASE Pharmaceuticals was founded by Thomas N. Chase.
- Who are CHASE Pharmaceuticals's investors?
- CHASE Pharmaceuticals's investors include Andera Partners, Brain Trust Accelerator Fund.
- How much funding has CHASE Pharmaceuticals raised?
- CHASE Pharmaceuticals has disclosed $21.6M raised across 3 of its 5 known rounds.
- Where is CHASE Pharmaceuticals headquartered?
- CHASE Pharmaceuticals is headquartered in Washington, US.